“In the first quarter of 2025, we executed a focused realignment of our operations to concentrate resources on our highest-value opportunities and extend our cash runway and position Biomea for long-term success,” said Mick Hitchcock, interim CEO and Board Member of Biomea Fusion (BMEA). “With icovamenib advancing in insulin-deficient type 2 diabetes patients and BMF-650 on track for IND submission, we are strategically positioned to deliver meaningful clinical data and drive value across our metabolic pipeline. These actions reflect our commitment to capital efficiency and developing the core therapies that we believe will have the potential to transform the lives of patients with diabetes and obesity.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion price target lowered to $3 from $11 at Barclays
- Biomea Fusion’s Strategic Shift: A Year of Transformation
- Biomea Fusion reports Q4 EPS (81c), consensus (93c)
- Buy Rating for Biomea Fusion’s Icovamenib: A Promising Breakthrough in Diabetes Treatment
- Biomea Fusion Appoints Interim CEO Amid Leadership Changes